(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 March 2010 (18.03.2010)

PCT

(10) International Publication Number
WO 2010/029335 A1

(51) International Patent Classification:
A61K 9/20 (2006.01) *A61P 19/02* (2006.01)
A61K 31/192 (2006.01) *A61P 1/04* (2006.01)
A61K 31/4439 (2006.01)

(21) International Application Number:
PCT/GB2009/051108

(22) International Filing Date:
3 September 2009 (03.09.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/095,584 9 September 2008 (09.09.2008) US

(71) Applicants *(for all designated States except US)*: **ASTRAZENECA UK LIMITED** [GB/GB]; 15 Stanhope Gate, London Greater, London W1K 1LN (GB). **POZEN INC.** [US/US]; 1414 Raleigh Road, Suite 400, Chapel Hill, North Carolina 27517 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **AULT, Brian** [US/US]; AstraZeneca R&D Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US). **ORLEMANS, Everardus** [NL/US]; POZEN INC., 1414 Raleigh Road, Chapel Hill, North Carolina 27517 (US). **PLACHETKA, John R.** [US/US]; POZEN Inc., 1414 Raleigh Road, Chapel Hill, North Carolina 27517 (US). **SOSTEK, Mark** [US/US]; AstraZeneca R&D Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US).

(74) Agent: **ASTRAZENECA INTELLECTUAL PROPERTY**; AstraZeneca AB, S-151 85 Södertälje (SE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— *with international search report (Art. 21(3))*

WO 2010/029335 A1

(54) Title: METHOD FOR DELIVERING A PHARMACEUTICAL COMPOSITION TO PATIENT IN NEED THEREOF

Figure 1



(57) Abstract: The present disclosure is directed to the use of naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof in the manufacture of a pharmaceutical composition in unit dose form, wherein said esomeprazole, or pharmaceutically acceptable salt thereof, is released from said unit dose form at a specified pH, wherein one unit dose form is for administration as an AM dose and a second unit dose form is for administration about 10 hours later as a PM dose to target a specified pharmacokinetic profile.